CURRICULUM VITAE

Personal details:

First names: Hamid Surname: Daneshvar
Date of birth: 5th September 1958
Nationality: Iranian, I have got Indefinite Residence Permit ion to stay in the UK
Marital status: Married Number of children: 3 Sex: Male.
Address: Department of Molecular and microbiology, Medical School of Kerman University, Kerman, Iran.
Tel: +98-341 2457789 Fax: + 98-341 3226171
Email: h.daneshvar@bio.gla.ac.uk

Degree(s):

B.Sc. Medical Technology, Beheshty University, Iran, (June 1981).
M.Sc. Medical Parasitology, Medical School of Kerman University, Iran, (June 1992).
Ph.D. Infection and Immunity, Glasgow University, UK, (August 2001).
Title of Ph.D. Thesis: Attenuation of Leishmania parasites and their use in vaccination studies.

Academic Experiences:

1993-1997: Instructor (Member of Academic Teaching Staff in Kerman Medical Sciences University, Kerman, Iran. Teaching of experimental and theoretical Immunology to medical students) (1993-1997).

Postdoctoral Research in the Division of Infection and Immunity University of Glasgow, UK, (April 2002- September 2002)..

Honorary Research Fellow in the Division of Infection and Immunity University of Glasgow, UK, (November 2002 - October 2003).

Assistant professor in Medical School of Kerman University, Kerman, Iran, (2003-present).

Head of Immunology Department of Kerman University of Medical Sciences (March 2008-2010).

Membership in scientific societies:
Membership of British Society for Immuonology.
Membership of Iranian Society for Tropical Disease.

Meeting Communication:
Attendance as WHO Temporary Adviser in Consultation Meeting on Live *Leishmania* Vaccines, Geneva, Switzerland, 3-4 June 2005.

Research Projects:
1- Evaluation of vaccine trail stage II the attenuated line of *Leishmania infantum* H-line in dog in Orzoieh city of Province of Kerman.

2- Evaluation of protection of *Leishmania infantum* H-line in the dog in Baft city of Province of Kerman.

3- Evalution of stabilizing and immunogenicity of the attenuated line of *Leishmania infantum* H-line in the calcium alginate beads.

4- Comparative study of inmune response of macrophage activated with *Leishmania mexicana* H-line or wild-type parasite.

5- Study of the human macrophage response against the attenuated *Leishmania infantum* in comparing with wild-type parasite

6- Survey of difference in proteins expression and its immunogenicity in *Leishmania infantum* wild type and *Leinshmania infantum* H-line in dogs.

7- Immunopathological study of *Leishmania infantum H-line* in German sheperd dog

8- Evaluation of protection of *Leishmania infantum* H-line in dogs excrementally infected with wild-type parasites.

9- Comparative study dendrtic vaccine exposed to *Leishmania major* H-line or *Leishmania major* wild-type.

10- Evaluation of infectivity of the attenuated line of *Leishmania infantum* in dog.

11- Evaluation of infectivity and protective immunogenicity of the attenuated line of *Leishmania major* in BALB/c mice.

12- Attenuation of *Leishmania* parasites and their use in vaccination studies.
Word Health Organization) (Project ID A10764 T25/181/1.

Technical skills/experience:
I have previously used the following techniques and I am familiar with their application:

A- Immunology:

Immunization mouse and dog, T-cell proliferation, Determination the level of antibody and cytokine using ELISA and immunofluorescence, western blotting,.

B- Proteomics:
Preparation sample, DIGE technique, and analysis data.

C- Genetic:
DNA extraction, nested PCR.

Computer skills:
I am proficient in the following programmes: Access and Excel databases, Word-processing, Power point, and graphic and presentation soft wares.

Publications:

1. **Daneshvar, H**., Namazi, MJ., Kamiabi, H., Burchmore, R., Cleaveland, S., Phillips, RS. 2014. Gentamicin-attenuated *Leishmania infantum* vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran. PLOS. Tro. Neg. Dis. (accepted).

2. **Daneshvar, H**., Mahmmodi, Z., Kamiabi, H., Phillips, RS., Burchmore, R. 2014. Dogs vaccinated with gentamicin-attenuated *Leishmania infantum* or infected with wild-type parasite can be distinguished by Western blotting. Parasite Immunol (accepted).

3. Jafarzadeh, A., Bagherzadeh, S., Ebrahimi, HA, Hajghani, H., Bazrafshani, MR., Khosravimashizi, A., Nemati M., Gadari, F., Sabahi, A., Iranmanesh, F., Mohammadi, MM, **Daneshvar, H**. 2014. Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern. J. Mol. Neurosci. DOI 10.1007/s12031-013-0214-2.

4. Momeni, M., Zainodini, N., Bidaki, R., Hassanshahi, GH, **Daneshvar, H**., Khaleghinia, M., Ebrahim, M., Karimi-Googheri, M., Askari, A., Kazemi Arababadi M., Kennedy, D. 2014. Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients. Human Immunol. 75: 15-19.

5. Karimi-Googherii, M., **Daneshvar, H**., Nosratabadi, R., Bidaki, M., Hassanshai, GH, Ebrahim, M., Kazemi Arababad I, M., Kennedy, D. 2014. Important roles played by TGF- β in hepatitis B infection. Medical Virol. 86: 102-108.

6. Jafarzadeh, A., Ebrahimi, HA., Bagherzadeh, S., Zarkesh, F., Iranmanesh, F., Najafzadeh, A., Khosravimashizi, A., Nemati, M., Sabahi, A., Hajghani, H., **Daneshvar, H**., Mohammadi, MM. 2013. Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: A comparison between patients and healthy women. Inflammation. DOI: 10.1007/s10753-013-9775-z.

7. Nosratabadi J. Sharifi, I., Sharififar, F., Bamorovat, M., **Daneshvar, H**., Mirzaie, M. 2013. In vitro antileishmanial activity of methanolie and aqueous extract of *Eucalytous camaldulensis* against *Leishmania major*. J Parasite. 10: 10-17.

8. Moradkhani, S., Mohammadi, MM., **Daneshvar, H**., Bazargan Harandi, N., Baneshi, MR. 2013. Evaluation of concentration of Proinflammatory/Pro Th1

cytokines IFN-γ and anti inflammatory/Pro Th2 Cytokines IL-13 and IL-4 in breast milk and their relationship to atopic dermatitis. TUMS J. 70: 640-651.

9. Nikpoor, AR., **Daneshvar, H**., Sanei Moghaddam, E., Askari, M., 2013. Assessment of requisition and consumption indices of blood in educational hospitals in Kerman city. Sci J Iran Blood Transfus Organ. 10: 12-19.

10. Hashemi, M, Atabaki, M., **Daneshvar**, H., Zakeri, Z., Eskandari-Nasab, E. 2013. Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheumatoid arthritis in Zahedan, Southeast Iran. Int J Immunogenet. 40: 299-305.

11. **Daneshvar H**., F. Sedghy, S. Dabiri, H. Kamiabi, MM. Molaei, R. Burchmore, S. Phillips. 2012. Alteration in mononuclear cell subpopulations in dogs immunized with gentamicin-attenuated *Leishmania infantum*. Parasitol. 139: 1689-1696.

12. **Daneshvar H**., S. Wyllie S. Phillips, P. Hagan, R. Burchmore. 2012. Comparative proteomics profiling of a gentamicin-attenuated *Leishmania infantum* cell line identifies key changes in parasite thiol-redox metabolism. J Proteomics. 75: 1463-1471.

13. Pardakhty A, Shakibaie M, **Daneshvar H**, Khamesipour A, Mohammadi-Khorsand T, Forootanfar H. 2012. Preparation and evaluation of niosomes containing autoclaved *Leishmania major*: a preliminary study. J Microencapsul. 29: 219-224.

14. **Daneshvar H**., MM. Molaei, H. kamiabi, R. Burchmore, P. Hagan, R. S. Phillips. 2010. Gentamicin-attenuated *Leishmania infantum*: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol. 32: 722-730.

15. **Daneshvar H**., R. Burchmore, P. Hagan, R. S. Phillips. 2009. *Leishmania major* H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent *Leishmania major*. Parasitology, 136: 1243-1250.

16. **Daneshvar H**., MM. Molaei, R. Melekpour, H. kamiabi, R. Burchmore, P. Hagan, R. S. Phillips. 2009. Gentamicin-Attenuated *Leishmania infantum*: a clinicopathological Study in Dogs. Veterinary Immunology and Immunopathology, 129: 28-35.

17. Phillips RS., **Daneshvar, H**., Hagan, P., Coombs, GH. 2003. Leishmaniasis. TDR-Final Report Series number 76.

18. **Daneshvar H**., P. Hagan, and R. S. Phillips. 2003. *Leishmania mexicana* H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice. Parasite Immnnology, 25: 589-596.

19. **Daneshvar H**., G. H. Coombs, P. Hagan, and R. S. Phillips. 2003. *Leishmania mexicana* and *Leishmania major*: attenuation of wild-type parasites and vaccination with the attenuated lines. Journal of Infectiou Disease, 187:1662-1668.

20. Keshavarz H., Mamishi, S., **Daneshvar, H**. 2000. The prevalence of toxoplasma infection in hospitalized patients in selected hospital of Kerman Iran.7: 132-137.

21. Sharifi I., **Daneshvar, H**. 1996. The prevalence of visceral leishmaniasis in suspected canine reservoirs in southeastern Iran. Iranian Journal of Medical Science,21: 134-138.

Published Abstracts (Conferences presentations):

1. Daneshvar H., P. Hagan, R. S. Phillips, and R. Burchmore. 2006. Proteomics changes in *Leishmania* species attenuated by gentamicin pressure. The XI International Congress of Parasitology. 6-11 August 2006, Glasgow, Scotland, UK.

2. Daneshvar H.,P. Hagan, and R. S. Phillips. 2005. *Leishmania mexicana* and *Leishmania major*: attenuation of wild-type parasites and vaccination with the attenuated lines. The first Meeting of Tropical Medicine and Immnunology. 8-10 Oct 1998, Iran, Abs. Book P.54.

3. Daneshvar H., Molaie M. Kamiabi H., Phillips RS., Burchmore R. 2010. Gentamicin-attenuated *Leishmania infantum*: production of a cellular immune response and protection against experimental visceral leishmaniasis infection in dogs. World Vaccine. China.

4. Daneshvar1, D., Molaei MM., Kamiabi1, H., Burchmore R., Hagan, P., Phillips, RS., Cellular immunity production and protective efficacy of *Leishmania infantum* H-line against experimental canine leishmaniasis in dogs. Japan.